BBIO: BridgeBio Pharma Inc

BBIO新闻

• 16:28 How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
• 16:35 Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
• 14:56 4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
• 08:57 Trump Expands Drug Pricing Agreements With 9 Drugmakers— RFK Jr. Says President Called ‘Every Hour’ to En
• 17:36 BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum
• 17:34 Is BBIO a Buy as Fast Sales Growth Meets a Steep Valuation Premium?
• 17:32 Why BBIO Rose 24% in Three Months and Whether the Rally Can Continue
• 16:49 BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 Months (NASDAQ:BBIO)
• 16:45 BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge
• 14:01 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
• 00:58 BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript
• 21:10 BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates